



ATOMO DIAGNOSTICS

(ASX:AT1)

DISCLAIMER

This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral communications transmitted or otherwise

made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contain certain forward looking statements that are based on Atomo’s beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).






WHO IS ATOMO?



ATOMO'S VISION, MISSION & VALUES


Empowering people to enjoy healthier, more informed lives through fast, accurate point of care testing.

We are re-imagining diagnostics by putting the user experience at the centre of everything we do. Atomo's mission is to ensure equitable and affordable access to accurate diagnoses and promote a seamless pathway to treatment.



IMPACT

Commercialising products that matter to our users




INNOVATION

Fostering creative thinking and solutions



INTEGRITY

Ensuring honesty and fairness in all that we do



COLLABORATION

Working as one global team



EXCELLENCE

Being recognised as experts in the field



WHO IS ATOMO AND WHAT DOES IT DO?

Atomo Diagnostics Limited is an innovative medical device diagnostics company supplying unique, integrated rapid diagnostic test devices and finished point-of-care rapid tests to global partners and consumers

WHO IS ATOMO?

- Headquartered in Australia and listed on the ASX, Atomo develops, manufactures and sells innovative rapid tests and unique test devices in point of care testing markets
- Atomo's solutions recognised as delivering best-in-class usability, accuracy and self-testing approvals
- A global company with commercial resources in the US, UK & Europe; and an Atomo facility in South Africa
- Atomo's products offer a significant growth opportunity as the market continues to shift to decentralised and at-home testing post-pandemic

WHAT DO WE DO?

Atomo's strategic focus is on two revenue generators:

- **Point of Care Test Products**
HIV, pregnancy and ferritin tests for POC and at-home self-test, distributed through an expanding global network, with more clinical applications to come
- **Point of Care Test Platform Technology**
Unique blood and swab test devices and components, sold to partners with capability to incorporate other indications



ATOMO'S JOURNEY

2010 - 2016

- Design, development and validation of Atomo's integrated rapid test technology

2017


- Atomo HIV Self Test approved for CE marking by European regulators
- Atomo and Access Bio announce partnership to expand HIV testing in low and middle income countries
- Atomo HIV Self Test launched in Europe

2018

- Atomo announces distribution partnership for HIV self-testing with Mylan for LMIC market
- Australian TGA approves Atomo HIV Self Test as first for sale in Australia
- Commencement of initial sales to HIV distribution partners


2019

- HIV Self Test secures WHO prequalification
- Commenced in-house assembly packing facility in Cape Town



ATOMO LEADS DISRUPTIVE INNOVATION IN RAPID TESTING

Atomo has developed best-in-class rapid tests that transform ease of use and reliability



“The lancet would not be out of place in a Christmas cracker”

Home allergy test - Boots feedback page, UK

“I would rather pay for this test in future (than use a free test) if it means it is this easy”

Atomo HIV Self Test user - Feefo, UK

ISSUES WITH STANDARD RAPID TEST KITS

- COMPLEX:** Multiple components, too many steps, requires expertise
- HIGH ERROR RATES:** Difficulties securing regulatory approvals and customer acceptance

ADVANTAGES OF ATOMO’S PRODUCTS

- SIMPLE & RELIABLE:** Intuitive to use, delivering accurate performance in the hands of untrained users
- UNIQUE:** The only fully integrated blood test for lateral flow applications



DRIVERS OF THE ADOPTION OF RAPID TESTING

Adoption of decentralised testing driven by ease of use, speed and accessibility


WHAT DRIVES ADOPTION OF RAPID TESTING¹



ATOMO'S PASCAL DEVICE VS. COMPETITORS

An independent study was conducted to validate Atomo's Pascal device usability when compared to a standard multi-component CE marked self-test.

The study was conducted by an independent Australian CRO with 50 untrained participants performing a rapid blood test for the first time.



¹ https://www.ipsos.com/sites/default/files/ct/news/documents/2022-03/Ipsos_Future%20of%20POC%20and%20Rapid%20Testing_March%202022.pdf

ATOMO'S UNIQUE CORE CAPABILITIES DRIVING SUCCESS

Atomo has commercialised rapid blood tests and products that are unmatched in the market

INNOVATION

COMMERCIAL SUCCESS



ATOMO DNA & IP

POINT-OF-CARE SELF TESTING

- Design and engineering
- Patents and know-how
- User centric design
- Co-development
- Regulatory processes
- Device manufacture

CORE FUNCTIONALITY

- Blood collection
- Saliva & swab collection
- Custom reagent blisters
- Interlocks to control steps of use
- Manufacturing machinery and processes
- IFUs
- Digital, home-use apps

TEST TECHNOLOGY

- Integrated blood test devices (single and multi-test formats)
- Integrated swab test device

PIPELINE*

- Blood collection device
- Saliva test device

FINISHED PRODUCTS

- HIV
- Pregnancy
- COVID-19

PIPELINE*

- Iron deficiency (ferritin)
- Vitamin D
- Others

MARKET ACCESS

- Supply agreements for Finished Test Products in more countries
- Commercialisation/supply agreements for devices
- White label partnerships in eHealth channels
- **New distribution relationship with Newfoundland in 2023 for HIV Self Tests in Europe**

**Products under commercialisation*



ATOMO'S OEM TECHNOLOGY BUSINESS


Atomo offers partners a broad range of unique products that fundamentally improve rapid testing



BLOOD TEST SOLUTIONS

A range of proprietary integrated blood test devices proven to reduce common errors with rapid testing and improve usability, especially with untrained self-test users

Commercialised across an increasing range of clinical applications




SWAB TEST SOLUTIONS

Portfolio of patents and device development that improve swab and saliva rapid testing

Supports a broad range of swabs with multiple test applications

Compatible with existing standard cassettes in market



BLISTER SOLUTIONS

Direct supply opportunity to OEM device partners and POC cassette developers

Frangible seal delivers best in class precision and multi-stage reagent delivery

Co-commercialisation/license



DIGITAL HEALTH OFFERINGS

Video of user steps. Image Recognition to interpret results (removes user errors and improves precision)

Semi-Quantitative results. Patented Blood delivery QC algorithm



ATOMO'S HIV SELF TEST COMMERCIALISED AND SOLD GLOBALLY

Atomo has developed and successfully launched the world's first integrated, blood-based HIV Self Test which is now registered in 46 countries with over 1.5 million units sold*



With regulatory approvals including CE Mark for Europe, Australian TGA and prequalification by the World Health Organization, the company's HIV business is poised to grow rapidly



Finished product assembly is carried out at the company's certified facility in South Africa, reducing the product cost of goods and logistics effort to supply volume into key global health markets



Atomo's HIV Self Test has been registered by Viatris in more than 39 LMIC countries (in addition to Europe and Australia outside of Viatris)



HIV self-testing is increasingly being used by public health bodies around the world to scale up testing




Atomo is now focused on further expansion of its HIV business and is seeking partners to support launch in remaining markets, including the US, Brazil, Mexico and China

* Excludes Professional Use tests sold



FUTURE PRODUCT ROADMAP

Atomo has a strong pipeline of product development moving beyond infectious diseases to target women’s health and at-home wellness monitoring



ATOMO'S BUSINESS: DE-RISKED, VALIDATED AND SCALING



PRODUCT RISK

STATUS

Designed to address user challenges with decentralised testing – now commercialised across a range of applications with registrations in more than 40 countries

EXAMPLES/COMMENTS

Extensive positive customer experience
Successful regulatory review and audit and approvals in multiple jurisdictions



REVENUE / SALES RISK

STATUS

Increasing HIV test sales, existing OEM customers purchasing devices, emerging consumer focus

EXAMPLES/COMMENTS

Global health contract in place. Tesco and other retailers to stock Atomo manufactured HIV and other self-tests



MARKET RISK

STATUS

Key stakeholders now support home testing with strong tailwinds such as growing consumer interest, public health adoption & procurement and regulatory acceptance of testing at-home

EXAMPLES/COMMENTS

TAM very significant, with >2bn rapid tests per annum globally with strong growth anticipated in the consumer segment



REGULATORY RISK

STATUS

Class IV (highest) approvals in place for Europe, Australia and WHO PQ (HIV Self-Test) with a number of clinical applications approved on Atomo cassettes for both professional and self-test, and US 410k pending end of 2023

EXAMPLES/COMMENTS

HIV Self Test
COVID Antibody Test
hCG Pregnancy Self Test
FebriDX AMR



USER ACCEPTANCE

STATUS

Performance independently established with common user errors reduced by 90% and overwhelmingly acknowledged by the vast majority of consumers as 'easier to use'

EXAMPLES/COMMENTS

User error rates significantly reduced
Consumers prefer the Atomo test



DISRUPTION RISK

STATUS

Extensive IP portfolio and proprietary know how protects first mover advantage, with industry leading usability and human factors expertise

EXAMPLES/COMMENTS

Patent protection globally across 5 patent families covering all key healthcare markets



TECHNOLOGY RISK

STATUS

Volume supply across various applications, with functionality and reliability now established. Atomo's finished products combine Atomo devices with well accepted commercialised rapid test assay

EXAMPLES/COMMENTS

More than 5 million tests delivered






ATOMO'S MARKETS



THE DIAGNOSTIC TEST LANDSCAPE

The COVID-19 pandemic caused a step change in healthcare: lower costs, increased convenience and proven efficacy of at-home healthcare, diagnosis and treatment is now embedded in the ecosystem




¹ McKinsey & Co. Telehealth: A quarter-trillion-dollar post COVID-19 reality May, 2022



THE HOME TEST MARKET - RESPONDING TO CONSUMER DEMAND

New and incumbent industry players increasingly focused on at-home consumer test market




Abbott, BD, Quidel pursue DTC strategies amid 'paradigm shift' for at-home, self-testing

The three test makers said at last week's J.P. Morgan conference they see opportunities for direct-to-consumer, digitally-connected testing for diseases beyond COVID-19.



Test on Your Terms

At-home tests for wellness, nutrition, fertility, STDs and more. No copays, ever.



** The slide depicts general examples, not only specific Atomo Diagnostics products, customers or channels*



ATOMO'S MARKETS: RAPIDLY GROWING POINT OF CARE DIAGNOSTICS

Global point-of-care markets present a significant opportunity for HIV, pregnancy and other emerging rapid test applications



- POC testing has experienced accelerated growth during and post the pandemic and is the fastest growing segment of the diagnostics market
- Growing demand for reliable, rapid diagnostic testing for patients at-home, further supported by an expanding telehealth segment and favourable reimbursement trends
- Providers, payers, regulators, investors and, most importantly, consumers, now understand the unique role of point-of-care and at-home testing in the delivery of accessible convenient healthcare
- Atomo is seizing the opportunity to supply reliable novel solutions for rapid testing in HIV, pregnancy and iron deficiency

1. Point-of-Care Testing (POCT) Market, October 2022, Precedence Research


2. HIV Diagnostics Market Outlook, May 2022, Future Market Insights

3. Pregnancy Testing Market, January 2022, Market Data Forecast

HIV MARKET OPPORTUNITY

Ending HIV requires communities to test early, and test often

HIV DIAGNOSTICS GLOBAL MARKET SIZE¹ (REVENUE AUD²)



- HIV self-test is a growing segment in low and middle income countries (LMIC) with annual demand expected to be 27 million tests by 2029³
- Atomo's HIV Self Test has been registered by Viatris in more than 39 LMIC countries (in addition to Europe and Australia outside of Viatris)
- New guidance on preferred purchasing of African manufactured HIV tests helping Atomo to secure global funder interest

ATOMO'S OPPORTUNITY

- Atomo has approvals including CE Mark for Europe, Australian TGA and WHO prequalification, and is seeing growth across its global HIV business
- During the COVID-19 pandemic, testing rates were down and incidence was up for STIs, including HIV. Post-COVID-19, point of care testing is increasingly seen as an essential screening tool
- Estimates on HIV rapid testing requirement of ~3 million tests per year in the US, with only one test currently approved for OTC self-test use
- Increased adoption of self-testing as a means to cost effectively increase test rates, with governments (including US and UK) now directly procuring and distributing HIV self-tests

¹ HIV Diagnostics Market Outlook, May 2022, Future Market Insights

² USDAUD 1.48


³ https://www.theglobalfund.org/media/5878/psm_productshiv-who_list_en.pdf



PREGNANCY MARKET OPPORTUNITY

Atomo’s early detection pregnancy test has a material opportunity to create a premium niche in the valuable female healthcare market

GLOBAL PREGNANCY TESTING MARKET SIZE¹ (REVENUE AUD²)



- The US with around one-third of the global market share (2021) performs more than 30 million rapid pregnancy self-tests each year
- Increased focus on earlier pregnancy detection given recent changes to the US landscape for women’s health
- No early detection pregnancy blood self-test commercialised in developed healthcare markets

ATOMO’S OPPORTUNITY

- Atomo has experience in expanding distribution partnerships across professional-use and OTC retail channels
- Priority on approval in ANZ markets, with submission to TGA underway and approval anticipated later this calendar year. The Australian pregnancy test market is estimated at more than 5 million tests annually
- Only one test provider has approval for a blood pregnancy test in the US (not CLIA waived, or OTC self-test approved)
- Atomo’s pregnancy test partner, NG Biotech, seeing increased demand in France, as well as further expansion and sales including a recent product launch in Brazil and UK launch later this year

¹ 1 Market Data Forecast Global Pregnancy Testing Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report, January 2022

² USDAUD 1.48



FERRITIN MARKET OPPORTUNITY

Providing an accurate, easy way to monitor your iron levels

THE INCREASING NEED FOR RAPID FERRITIN TEST SOLUTIONS



- World Health Organization research suggests anaemia affects 30% of all women worldwide. This number rises to more than 40% in pregnant women¹
- Ferritin is listed as a “Top 10 most requested tests” ordered by doctors in the USA² and has been regularly referenced in Atomo’s consumer partner discussions
- The global iron deficiency anemia therapy market size was valued at USD 1.93 billion in 2019 and was expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2020 to 2027.³ This figure only represents the size of the iron deficiency anemia therapy market, which is only one aspect of the iron deficiency market as a whole.

ATOMO’S OPPORTUNITY

- Atomo is targeting near-term approval and launch in Australia, NZ, the UK and Europe, and is confident of achieving significant unit sales in a short time frame.
- Market feedback from the UK and Europe has evidenced compelling demand for ferritin tests and strong interest in Atomo’s product.
- Atomo will utilise the established Galileo test platform and existing infrastructure and capacity at the South African manufacturing facility to produce Atomo branded product, thus resulting in low incremental cost for new revenues

¹ Worldwide prevalence of anaemia 1993-2005 WHO Global Database on Anemia/Edited by Bruno de Benoist, Erin McLean, Ines Egli and Mary Cogswell

² <https://www.findlabtest.com/article/top-10-blood-tests-ordered-by-doctors/>

³ Grand View Research. (2020). Iron Deficiency Anemia Therapy Market Size, Share & Trends Analysis Report By Product (Oral Iron Therapy, Parenteral Iron Therapy), By Region (North America, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2020-2027.



TARGET MARKET OPPORTUNITIES

Providing a portfolio of tests in large, repeat-use monitoring and screening markets

SEXUAL HEALTH

- HIV
- HIV/syphilis (combination blood device)
- Chlamydia/gonorrhea (combination swab device)

FEMALE HEALTH

- Pregnancy
- Thyroid (TSH) monitoring
- Vitamin D

OTHERS

- Gluten intolerance
- Testosterone monitoring
- PSA (prostate health) monitoring

Atomo's portfolio of tests enable people to test early and test often, putting healthcare in the hands of the consumer

Red text indicates products already launched






MAKING AN IMPACT



MAKING AN IMPACT

With experience in rapid test technology, Atomo has runs on the board



ENVIRONMENTAL, SOCIAL & GOVERNANCE

The company has identified the following sustainability issues most material to its business and are important to key stakeholders such as investors, consumers, customers, supplier, governments and employees.



PRODUCT QUALITY & SAFETY

Choosing materials from quality sources, complying with ISO 13485 Medical Devices Quality Management, and delivering safe products to customers and investigates all concerns to ensure our products maintain the highest quality



PRODUCT PRICING & ACCESSIBILITY

Strategies and initiatives designed to provide more affordable diagnostic pricing and accessibility to products for patients through development, manufacture and marketing of high-quality generic and branded products, with a particular focus on accessible diagnostics for the global health and Lower and Middle Income markets



SAFE & HEALTHY EMPLOYMENT

Ensuring our employees work in a safe environment with opportunities for training and growth, addressing health and safety concerns as they arise and mitigates the risk of re-occurrence of incidents



ETHICAL PURCHASING & HUMAN RIGHTS IN THE SUPPLY CHAIN

Responsibility to partners to ensure our product line is free from human rights concerns such as forced labour and trafficking, unsafe labour standards and unfair treatment



CORRUPTION & BRIBERY

Ethical business practices relate to every aspect of Atomo's business, from identifying product sources, through the development of diagnostics, transactions with regulatory bodies and sale to customers



COMPLIANCE

Responsibility to drive compliance with legal and regulatory requirements applicable to our global business. Includes development of policies and controls, communication and training, oversight and continuous improvement



RESOURCE USE & WASTE MANAGEMENT

Includes energy usage during manufacture and logistics, water usage and waste as a by-product of manufacture, with particular consideration given to the fact that the products are classified as medical waste upon use



ENVIRONMENTAL REGULATION

Focused on meeting or exceeding environmental regulation across its operations globally



ESG - CASE STUDIES

Atomo's approach to ESG issues is consistent with the ambition of being an organisation for profit and for purpose

Atomo operates from its facility in South Africa where jobs have been created with opportunities for training, upskilling and growth



Efficient local African production allows world leading, life saving products to be sold to lower-middle income markets at accessible prices

*"Access to HIV self-tests significantly expanded and costs halved thanks to Unitaid agreement"*¹



As a producer of a product that becomes medical waste once used, Atomo's challenge is to reduce its environmental footprint

Recent project targeting plastic, paper and CO2 reduction led to 3 initiatives:



- Reduction in size and number of instructions for use document without compromising usability
- Elimination of requirement for plastic disposal bag
- Pallet recycling program reducing resource requirement and CO2 footprint



¹ <https://unitaid.org/news-blog/access-to-hiv-self-tests-significantly-expanded-and-costs-halved-thanks-to-unitaid-agreement/#en>



SOUTH AFRICAN OPERATIONS

QMS


All processes are validated, verified and audited by major SRA (WHO, TGA & BSI)

PRODUCTION RAMP UP

Experience with scale-up and tech transfer

PRODUCED IN AFRICA

Atomo's HIV Self Test is manufactured in Cape Town, South Africa



SAP INTEGRATION

End to end product and batch traceability
Inventory management

LOCAL SUPPLY CHAIN

Local procurement distribution and storage
Reduced costs, lead time and environmental footprint to deliver PQ'd HIV tests to Africa

EXPERIENCED & SKILLED STAFF

Employment, training and skills transfer to a local, mainly female workforce in South Africa




KEY METRICS


- Early revenue from first commercialisation of HIV Self Tests in the South African domestic market in FY19
- Non-COVID revenue growth impacted during FY20-FY22 by diversion of funding and attention to COVID-19 testing
- Pivot to COVID-19 testing led to significant contribution to revenues during FY20-FY22
- FY23 return to quarterly growth in non-COVID-19 revenue
- Cash of \$8.9m and no debt
- Roll out plan for new products in FY24 and FY25 to drive additional growth beyond HIV and OEM

Atomo anticipates reaching breakeven operating cashflow using its current capacity and resources, with target margins at 50% and steady state opex of around \$750k per month. After that, the company is leveraged to profitability with further growth not requiring a significant increase in headcount or investment

ANNUAL REVENUE (A\$m)



PRODUCT MIX



KEY INVESTMENT HIGHLIGHTS

- Atomo actively participates in an **expanding global rapid testing market** driven by significant industry and consumer tailwinds
- **Atomo has patent protected user friendly testing technology**, with multiple OEM contracts, a strong pipeline and emerging channel partner demand
- Best-in-class usability offers the opportunity for **first approved OTC blood tests in the US market**, starting with pregnancy
- **Highly regarded finished products with regulatory approval for high volume applications**, including HIV screening and blood-based early pregnancy detection
- Well progressed with **commercialisation of a range of home tests** with channel partners indicating demand, driving further revenue growth and diversification
- **Regulatory certified, low cost manufacturing in place** and easily scaled to significant operational leverage and margin growth in the near term (without further capital expenditure)
- Atomo has completed its intensive manufacturing CapEx phase - **future investment focused on commercialising new products, driving revenue growth and delivering investor returns**





APPENDIX



ATOMO DIAGNOSTICS CORPORATE AND EXECUTIVE INFORMATION



JOHN KELLY

CHIEF EXECUTIVE OFFICER

Before founding Atomo Diagnostics in 2010, John was Chief Operating Officer at ASX listed (now NASDAQ listed) Unilife Corporation. Previously, John led the New Product Implementation Group at ResMed. In addition to his commercial experience, John has an Honours Degree in Mechanical Engineering from the University of Liverpool, a Master’s Degree in Systems Engineering from Queen’s University Belfast, and an Executive MBA from the University of Sydney



WILL SOUTER

CHIEF FINANCIAL OFFICER

Experienced senior finance executive, lawyer and investment banker. Most recently Will was Chief Financial Officer for property and construction tech company, Vertron Technologies. Previously Executive Director at RFC Ambrian. Prior to RFC, Will was a Director at PwC over a 10-year period in London and Sydney, and worked at Minter Ellison Lawyers. Graduate of the AICD, admitted to the Supreme Court of NSW. Will holds a Bachelor of Laws, and a Bachelor of Commerce from the University of Adelaide



CHANDRA SUKUMAR

CHIEF OPERATING OFFICER

Chandra joined Atomo in 2017 as Director of Programs bringing with her more than 25 years of experience within the medical device industry. She has extensive experience in the development of medical devices from conception to commercialisation. Prior to joining Atomo, she served in a variety of leadership roles within ResMed, including supply chain management, global manufacturing, and APAC marketing. Chandra holds a Bachelors Honours degree in Physics and an executive MBA from AGSM.

KEY FINANCIAL INFORMATION

ASX Code	AT1
Share Price	A\$0.04
Shares on Issue	570.9m
Options on Issue	9.6m
Market Cap*	A\$23m
Current Cash (31/03/2023)	\$8.9m

*Undiluted

MAJOR SHAREHOLDERS

% (UNDILUTED)

Dalraida Holdings Pty. Ltd.	12.7%
Global Health Investment Fund I, LLC	11.4%
GZ Family Office	8.1%
Walker Group	6.6%

- Founded in 2010 in Sydney, Australia
- Established global footprint with corporate and primary office in Sydney, production in South Africa and established presence in UK and US
- Listed on the ASX in April 2020
- ~8k shareholders with a mix of institutional, family office and retail



ATOMO DIAGNOSTICS BOARD OF DIRECTORS



JOHN KEITH

NON-EXECUTIVE CHAIR

John is the Managing Director of BNP Paribas establishing and leading its financial institutions coverage team. Prior to that, he led management and coverage roles for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking John also serves as a Director of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation



DR. CURT LABELLE

NON-EXECUTIVE DIRECTOR


Dr. LaBelle has been actively involved in the healthcare industry for 20 years, both operationally and as an investor. He is the Managing Partner at the Global Health Investment Fund, JP Morgan and others. He also serves as a director on the boards of Alydia Health, Atticus Medical and Eyenovia. Prior to joining GHIF, Dr. LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital.



DEBORAH J. NEFF

NON-EXECUTIVE DIRECTOR

A veteran of the life sciences industry building market-leading global businesses. Non-Executive Director of Cytek Biosciences Inc. Non-Executive Director of Guide Dogs For The Blind Inc. As principal of DJN Consulting, LLC, Deborah works with several healthcare startup companies providing strategic business advice to and mentoring the executive management team. Previously CEO of Evanostics, LLC., Pathwork Diagnostics Inc., and COO at Complete Genomics Inc., following a 15-year career with Becton Dickinson Inc.



DR. CHERI WALKER

NON-EXECUTIVE DIRECTOR

Dr. Walker is an executive with more than twenty-five years of experience working with life science and diagnostic companies. Dr. Walker is currently the President, Chief Executive Officer, and Director of Rhinostics. She has previously held senior executive positions at Abcam; Charles River Labs; Qiagen, and Life Technologies, now part of ThermoFisher. Dr. Walker holds a BA in Biology from Swarthmore College and a Ph.D. in Human and Molecular Genetics from Baylor College.



DR. PAUL KASIAN

NON-EXECUTIVE DIRECTOR

Chair of IODM Limited. Non-Executive Director of Eco Systems Ltd (ASX:ESL). Executive Chairman of Zucero Therapeutics Limited. Previously Chair and CEO of Genetic Technologies Limited. PhD in Microbiology and MBA, both from the University of Melbourne, and GAICD. Former Chief Investment Officer and Head of Global Financials at HSBC Asset Management; Founding Director of Accordius; Founding Director of Wallara Asset Management.

